a women looking to the left and slightly smiling

Scientific publications

A robust body of evidence highlights the potential of psychedelics as transformative treatments for mental health conditions.

Szabo et al., The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells (2016)

Argento et al., Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada (2019)

Palhano-Fontes et al., Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression (2019)

Timmermann et al., Neural correlates of the DMT experience assessed with multivariate EEG (2019)

Pallavicini et al., Neural and subjective effects of inhaled DMT in natural settings (2020)

Pasquini et al., Subacute effects of the psychedelic ayahuasca on the salience and default mode networks (2020)

MAPS, MAPS – MDMA Investigator’s Brochure (10th Edition) (2018)

Rudnick & Wall, The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release (1992)

Carhart-Harris et al., The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity (2015)

Mitchell et al., MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)

Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023)

Bowen, et al., Discovery of novel 5-HT2A receptor agonists with non-hallucinogenic potential and translational antidepressant drug-like profiles

Bowen, et al., Novel 5-HT2A receptor agonists exhibit translational antidepressant and psychedelic drug-like profiles in a model of treatment-resistant depression (2023)

Bowen, et al., Discovery of novel 5-HT2A receptor agonists with psychedelic drug-like in vitro and in vivo pharmacological activity and therapeutic potential for treatment-resistant depression (2023)

Bowen, et al., Discovery of novel 5-HT2A receptor modulators for the treatment of mood disorders

Our research is focused on developing rapid-acting, effective and durable mental health treatments for large-scale patient impact.

We focus on mental health disorders where patients have limited or no effective treatment options and little hope for a better future. We are committed to leading a new era of mental health treatment – one that offers not only relief from symptoms, but lasting change and a life full of possibility.

Therapeutic areas